-
Thematic Analysis
NewPsychedelics Therapeutics Development and Trends, 2024
This report provides a summary of the current and future state of the psychedelic therapeutic sector, offering a high-level analysis of key trends and developments within the industry, including regulatory, clinical, and market dynamics. The report identifies the broader changes within the evolving psychedelic industry, facilitating informed decision-making for relevant sectors.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Post-Traumatic Stress Disorder (PTSD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Post-Traumatic Stress Disorder (PTSD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Post-Traumatic Stress Disorder (PTSD) Drug Details: Psilocybin is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Obsessive-Compulsive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Obsessive-Compulsive Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Obsessive-Compulsive Disorder Drug Details: Psilocybin is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HuMNC2-CAR22 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HuMNC2-CAR22 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HuMNC2-CAR22 in Triple-Negative Breast Cancer (TNBC) Drug Details: huMNC2-CAR22 (MUC1*-CAR-1XX)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Body Dysmorphic Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Body Dysmorphic Disorder report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Body Dysmorphic Disorder Drug Details: Psilocybin is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Anorexia Nervosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Anorexia Nervosa report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Anorexia Nervosa Drug Details: Psilocybin is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Treatment Resistant Depression
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Psilocybin in Treatment Resistant Depression report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Treatment Resistant Depression Drug Details: Psilocybin is under...
-
Product Insights
Treatment Resistant Depression – Drugs In Development, 2023
Global Markets Direct’s, ‘Treatment Resistant Depression - Drugs In Development, 2023’, provides an overview of the Treatment Resistant Depression pipeline landscape. The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Appetite (Eating) Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Appetite (Eating) Disorders - Drugs In Development, 2023’, provides an overview of the Appetite (Eating) Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Appetite (Eating) Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Autism Spectrum Disorder (ASD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Autism Spectrum Disorder (ASD) - Drugs In Development, 2023’, provides an overview of the Autism Spectrum Disorder (ASD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Autism Spectrum Disorder (ASD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...